Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma

Medical Oncology

Volumn 32, Issue 4, 2015, Pages

  Lou, Yuqing ^a   Li, Rong ^a   Liu, Jielin ^b   Zhang, Yanwei ^a   Zhang, Xueyan ^a   Jin, Bo ^a   Liu, Ya ^b   Wang, Zuoguang ^b   Zhong, Hua ^a   Wen, Shaojun ^b   Han, Baohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b BEIJING INSTITUTE OF HEART   (China)

Author keywords

Cell cycle; Cell invasion; Lung adenocarcinoma; MFN2; Microarray

Indexed keywords

MITOFUSIN 2; GUANOSINE TRIPHOSPHATASE; MESSENGER RNA; MFN2 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; SMALL INTERFERING RNA;

ADULT; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE; CELL CYCLE REGULATION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MICROARRAY ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL ADHESION; CELL MOTION; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84938080852     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0515-0     Document Type: Article

References (33)

1. Cagle PT, Allen TC, Beasley MB, Chirieac LR, Dacic S, Borczuk AC, et al. Molecular pathology of lung cancer. Molecular pathology library. New York: Springer; 2012.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int du Cancer. 2010;127(12):2893–917. doi:10.1002/ijc.25516.
3. Minna JD. Molecular pathogenesis of lung cancer with translation to the clinic [videorecording]. New Haven: MedMedia Services, Yale University School of Medicine, 2007.
4. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107–20. doi:10.1016/j.cell.2012.08.029.
5. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50. doi:10.1038/nature13385.
6. Li L, Wei Y, To C, Zhu CQ, Tong J, Pham NA, et al. Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nat Commun. 2014;5:5469. doi:10.1038/ncomms6469.
7. Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. J Cell Sci. 2001;114(Pt 5):867–74.
8. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, et al. Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol. 2004;6(9):872–83. doi:10.1038/ncb1161.
9. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004;36(5):449–51. doi:10.1038/ng1341.
10. Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem. 2003;278(19):17190–7. doi:10.1074/jbc.M212754200.
11. Hernandez-Alvarez MI, Thabit H, Burns N, Shah S, Brema I, Hatunic M, et al. Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1 alpha/mitofusin-2 regulatory pathway in response to physical activity. Diabetes Care. 2010;33(3):645–51. doi:10.2337/Dc09-1305.
12. Chien KR, Hoshijima M. Unravelling Ras signals in cardiovascular disease. Nat Cell Biol. 2004;6(9):807–8. doi:10.1038/Ncb904-807.
13. Wu L, Li ZX, Zhang YM, Zhang P, Zhu XH, Huang J, et al. Adenovirus-expressed human hyperplasia suppressor gene induces apoptosis in cancer cells. Mol Cancer Ther. 2008;7(1):222–32. doi:10.1158/1535-7163.Mct-07-0382.
14. Jin BY, Fu GH, Pan H, Cheng XF, Zhou L, Lv J, et al. Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma. Med Oncol. 2011;28:S373–80. doi:10.1007/s12032-010-9662-5.
15. Wang WL, Lu JJ, Zhu F, Wei JF, Jia CK, Zhang YB, et al. Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells. Med Oncol. 2012;29(1):70–6. doi:10.1007/s12032-010-9779-6.
16. Haapa-Paananen S, Kiviluoto S, Waltari M, Puputti M, Mpindi JP, Kohonen P, et al. HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. Oncogene. 2012;31(10):1299–310. doi:10.1038/Onc.2011.316.
17. Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013;24(10):2589–93. doi:10.1093/annonc/mdt295.
18. Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA. 2008;105(12):4826–31. doi:10.1073/pnas.0712365105.
19. Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 2010;10:370. doi:10.1186/1471-2407-10-370.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
21. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362–74. doi:10.1038/nrc1075.
22. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500. doi:10.1126/science.1099314.
23. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–703. doi:10.1056/NEJMoa1006448.
24. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630–5. doi:10.1158/2159-8290.CD-13-0035.
25. Xia Y, Wu Y, He X, Gong J, Qiu F. Effects of mitofusin-2 gene on cell proliferation and chemotherapy sensitivity of MCF-7. J Huazhong Univ Sci Technol [Med Sci]. 2008;28(2):185–9. doi:10.1007/s11596-008-0218-2.
26. Ma L, Liu Y, Geng C, Qi X, Jiang J. Estrogen receptor beta inhibits estradiol-induced proliferation and migration of MCF-7 cells through regulation of mitofusin 2. Int J Oncol. 2013;42(6):1993–2000. doi:10.3892/ijo.2013.1903.
27. Zhang GE, Jin HL, Lin XK, Chen C, Liu XS, Zhang Q, et al. Anti-tumor effects of mfn2 in gastric cancer. Int J Mol Sci. 2013;14(7):13005–21. doi:10.3390/ijms140713005.
28. Wang W, Zhou D, Wei J, Wu Z, Cheng X, Sun Q, et al. Hepatitis B virus X protein inhibits p53-mediated upregulation of mitofusin-2 in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2012;421(2):355–60. doi:10.1016/j.bbrc.2012.04.015.
29. Wang W, Zhu F, Wang S, Wei J, Jia C, Zhang Y, et al. HSG provides antitumor efficacy on hepatocellular carcinoma both in vitro and in vivo. Oncol Rep. 2010;24(1):183–8.
30. Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J Off Publ Fed Am Soc Exp Biol. 2012;26(5):2175–86. doi:10.1096/fj.11-196543.
31. Raaijmakers JH, Bos JL. Specificity in Ras and Rap signaling. J Biol Chem. 2009;284(17):10995–9. doi:10.1074/jbc.R800061200.
32. Small molecules inhibit the RAS-like small GTPases RALA and RALB. Cancer Discov. 2014;4(11):1251. doi:10.1158/2159-8290.CD-RW2014-199.
33. Girotti MR, Fernandez M, Lopez JA, Camafeita E, Fernandez EA, Albar JP, et al. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/alpha 2 beta 1 integrin axis. J Invest Dermatol. 2011;131(12):2438–47. doi:10.1038/Jid.2011.239.